PubMed Health⌕ Search

PubMed · 12666049

[Status epilepticus].

Abstract

Status epilepticus (SE) is one of the most important neurological emergencies. We describe the most recent aspects concerning the definition, classification, aetiology, physiopathological and epidemiological aspects of SE, together with the therapeutic principles and pharmacotherapy in adults and adolescents. The therapeutic control of SE becomes more difficult as its duration becomes longer, and the possibility of causing permanent neurological damage also increases. Treatment is more effective when it is performed following a protocol. The benzodiazepines are still a first line of treatment. Home care treatment of patients with recurring seizures or important risk factors for developing SE could help to improve the future response to therapy and, therefore, its prognosis. Thus, several therapies involving benzodiazepines are developed which can be administered rectally, nasally and sublingually. In the future, treatment may include the use of neuroprotective drugs that reduce the morbidity and mortality of SE and prevent cell death. In spite of the progress made in understanding SE, there are still certain shortcomings that must be solved, i.e. mistakes made during diagnosis, a need for wider availability of electrographic controls, the basic physiopathological mechanisms require further research, and controlled studies with currently available antiepileptic drugs and others that have only recently appeared should be conducted in order to evaluate their therapeutic effectiveness, in both home care and hospitalised patients (refractory SE).

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Tejeiro, B Gómez Sereno. [Status epilepticus].. https://pubmed.ncbi.nlm.nih.gov/12666049/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Properties of enteric coated sodium valproate pellets.

The influence of subcoat application and micro-environmental pH on the dissolution properties of enteric coated sodium valproate pellets was investigated. The pellets were prepared by solution-layering or wet-mass extrusion-spheronization methods. In order to pass the USP enteric test, the solution-layered and wet-mass extruded pellets required 35 and 25% weight gain of Eudragit L 30D-55, respectively. The application of a subcoat of either Methocel-E5 (HPMC) or Opadry AMB to the pellets resulted in a delay in sodium valproate release in 0.1N HCl. Further delay in drug release was observed when citric acid was present in a HPMC subcoat or when added to the core pellet formulation. The amount of drug released from coated pellets was a function of the level of citric acid in the pellet core or subcoat and subsequent micro-environmental pH of the pellets. Citric acid exerted a plasticizing effect on the enteric polymer film and improved film formation and polymer coalescence. When greater than 10% (w/w) citric acid was present in the pellets, a decrease in drug content was observed due to the conversion of sodium valproate to the volatile compound, valproic acid. Pellets containing less than 10% (w/w) citric acid maintained potency during processing.

Anticonvulsants↗

Determination of vigabatrin by capillary electrophoresis with laser-induced fluorescence detection.

A new analytical method for vigabatrin based on capillary electrophoretic separation and laser-induced fluorescence detection has been developed. 5-Carboxytetramethylrhodamine succinimidyl ester was used for precolumn derivatization of the non-fluorescent drug. Optimal separation and detection were obtained with an electrophoretic buffer of 50 mM sodium borate (pH9.5) containing 10 mM sodium dodecyl sulfate and a green He-Ne laser (excitation at 543.5 nm, emission at 589 nm). The concentration limit of detection in aqueous solution was 24 nM. Combined with a simple cleanup procedure, this method can be applied to the determination of vigabatrin in human plasma. A calibration curve ranging from 1.5 to 200 microM shown to be linear. Both the within-day and day-to-day reproducibilities and accuracies were less then 14.3% and 4.9% respectively. The limit of detection of vigabatrin in plasma was about 0.13 microM

Anticonvulsants↗